Why alcohol use disorder resists traditional treatment
Traditional recovery models often fall short because they address behavior without correcting the underlying neurobiological imbalance that drives craving. Alcohol use disorder (AUD) is not a failure of willpower—it’s a medical condition rooted in disrupted brain chemistry, specifically the balance between glutamate (the brain’s primary excitatory neurotransmitter) and GABA (its calming counterpart). When these systems are thrown off balance by chronic alcohol use, the brain’s reward circuits become deeply entrenched, making sustained sobriety extraordinarily difficult without physiological support.
The scale of the challenge is sobering. Approximately 29 million Americans live with AUD, yet only 8% ever seek treatment. Of those who do, relapse rates reach 40–60% —comparable to other chronic conditions like asthma or hypertension. These numbers reflect not personal weakness, but the powerful grip of glutamate alcohol dependency that conventional behavioral approaches alone cannot break.
Chronic alcohol exposure fundamentally alters how the brain processes reward and stress. Over time, drinking becomes less about pleasure and more about avoiding the discomfort of withdrawal—a cycle driven by neurochemical changes that no amount of willpower can override. Understanding this biological reality is the first step toward finding a treatment that works at the level of the brain itself. Nushama’s approach to ketamine therapy for alcohol use disorder addresses this neurobiological foundation directly.
The science of ketamine AUD treatment: glutamate and the KARE protocol
Ketamine works by chemically resetting the brain’s reward circuits and boosting neuroplasticity—the brain’s ability to form new connections—making the KARE (Ketamine for Alcohol Reduction) protocol a dual-action treatment that combines precision medicine with structured psychotherapy. Unlike medications that simply dampen cravings, ketamine modulates NMDA receptors—key gatekeepers of glutamate activity—helping to restore the neurochemical balance that chronic alcohol use disrupts. This is the mechanism behind what researchers call glutamate-targeted therapy: addressing the glutamate alcohol dependency at the root cause rather than just the symptoms.
When alcohol is consumed regularly over time, the brain compensates by downregulating GABA receptors and upregulating glutamate receptors. This adaptation creates a neurochemical imbalance where the brain becomes dependent on alcohol to maintain equilibrium. Ketamine interrupts this cycle by temporarily blocking NMDA receptors, which reduces the hyperactive glutamate signaling and allows the brain to begin recalibrating. To explore how these receptor mechanisms translate into therapeutic outcomes, see the neuroscience of ketamine in greater detail.
The evidence base for this approach spans three decades of research, beginning with the foundational Krupitsky ketamine research in the 1990s. In these landmark trials, participants who received ketamine achieved total alcohol abstinence for more than one year at a rate of 65.8%, compared to just 24% in the standard control group. More recent studies have confirmed these findings, with the 2022 Grabski trial demonstrating that three infusions of ketamine combined with therapy were well tolerated and associated with significantly more days of abstinence at six-month follow-up.
Ketamine rapidly increases levels of BDNF (Brain-Derived Neurotrophic Factor), a protein that promotes the growth and survival of brain cells. This surge creates what clinicians call a “critical window” in the days following treatment, during which the brain is uniquely receptive to forming new habits and perspectives. But ketamine alone is not a cure. The medicine opens the door; therapy builds the new room. This is why the KARE protocol pairs each infusion with mindfulness-based relapse prevention (MBRP), a therapeutic framework that teaches members to observe cravings without judgment and respond to stress without reaching for alcohol.
What a ketamine recovery journey for alcohol use disorder looks like
The KARE journey is a structured, medically supervised protocol that integrates precision medicine with psychotherapy to support the whole person. Unlike the prolonged disruption of inpatient rehab, this outpatient approach allows members to maintain their work and family commitments while receiving evidence-based care over four weeks. Each step is designed with both safety and efficacy in mind, from the initial medical screening to the final integration session.
Medical screening and intake
Recovery begins with a comprehensive psychiatric and medical evaluation to ensure that IV ketamine therapy is appropriate and safe. IV ketamine refers to ketamine administered intravenously—a delivery method that provides 100% bioavailability and allows clinicians to adjust dosing in real time. During this intake, our medical team reviews your history, current medications, and any contraindications such as uncontrolled hypertension or active psychosis.
Preparation sessions
Before the first infusion, you’ll meet with a therapist to set intentions, build trust, and develop a vision of life beyond alcohol. These sessions lay the groundwork for the psychotherapy that will accompany each ketamine journey. During preparation, you’ll explore what would your life look like without alcohol, what triggers your drinking, and what you’ve tried before.
The infusion phase (KARE protocol)
The core of treatment consists of three IV ketamine infusions, each paired with mindfulness-based psychotherapy, delivered over approximately four weeks. During the infusion, you’ll remain awake but enter a dissociative state—a dream-like condition in which ordinary boundaries between thoughts and sensations soften, creating space for new insights. A trained therapist stays with you throughout the session, and our medical team monitors your vitals continuously to ensure safety.
Research suggests the KARE protocol may support meaningful change in ketamine alcohol addiction recovery: the Grabski trial found that participants who received ketamine combined with therapy achieved 86% percentage of days abstinent (PDA) over six months, compared to approximately 76% in the therapy-only control group. Many members report that cravings diminish noticeably after the first or second infusion, and that the compulsive pull toward alcohol begins to loosen its grip.
Integration
Integration sessions help translate the insights from your ketamine journeys into concrete behavioral changes: identifying triggers, building support networks, and practicing mindfulness techniques. In the 24 to 72 hours following ketamine treatment, the brain enters a heightened state of neuroplasticity—a window during which new habits and coping strategies can take root more easily. To read more about the importance of ketamine integration , explore how this critical phase anchors therapeutic outcomes.
Addressing co-occurring conditions
Nushama treats co-occurring conditions such as PTSD, anxiety, and depression alongside alcohol use disorder because many people struggling with AUD also carry the weight of unresolved trauma. A 2025 study by Henry A MacConnel, Mitch Earleywine, and Steven Radowitz, titled “Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm,” found that IV ketamine may offer rapid and sustained relief for PTSD symptoms that have resisted other treatments.
Treating co-occurring conditions within the KARE protocol means that as you address your relationship with alcohol, you’re also working through the trauma, depression, or anxiety that may have fueled your drinking in the first place. For a detailed comparison, visit ketamine-assisted therapy vs. traditional rehab for AUD.
Comparing ketamine therapy to rehab and at-home models
For those seeking evidence-based results without the life disruption of inpatient rehab, medically supervised IV ketamine therapy offers a precise, cost-effective alternative grounded in peer-reviewed research. Traditional inpatient rehab can cost $25,000 to $50,000 per month, requiring members to leave work, family, and community for 30 to 90 days. In contrast, the KARE program costs approximately $9,950 and includes medical intake, three ketamine infusions, and 18 hours of mindfulness-based talk therapy—all delivered on an outpatient basis.
The delivery method also matters. IV ketamine provides 100% bioavailability, meaning the full dose reaches your brain immediately, and our medical team can adjust dosing in real time to ensure both safety and therapeutic benefit. This stands in contrast to at-home oral lozenges or nasal sprays, where absorption rates vary widely and members lack immediate medical oversight. To explore how ketamine works compared to classical psychedelics, consider the unique receptor mechanisms that distinguish ketamine from other therapeutic compounds.
At-home ketamine models offer flexibility but operate without continuous medical monitoring, meaning adverse reactions may go unnoticed. For people with AUD — where co-occurring conditions, medication interactions, and emotional volatility are common — in-clinic supervision provides an additional layer of safety and therapeutic support. The absence of a therapist during the session means that difficult emotions or memories may surface without professional support to process them safely. Equally important is the “integration gap” that plagues many at-home models—without structured therapy to help you process insights and build new coping mechanisms, the neuroplastic window may close without lasting change.
FAQs
These frequently asked questions address clinical considerations, safety protocols, and how ketamine-assisted therapy integrates with existing recovery approaches.
Q: Is ketamine addictive when used for alcohol use disorder?
A: In a clinical setting with controlled dosing and medical supervision, the addiction risk is extremely low. Ketamine does have a potential for misuse when taken recreationally in high doses, but the structured protocols used in medical treatment differ fundamentally from recreational use. Our care team monitors every session, and the mindfulness-based therapy component helps members develop healthier relationships with all substances.
Q: How does this differ from AA or 12-step programs?
A: The KARE protocol is a medical intervention that targets the neurobiological roots of addiction, while AA and other 12-step programs provide community support and behavioral frameworks. These approaches are not mutually exclusive—many members find that ketamine-assisted therapy complements their participation in AA by reducing the intensity of cravings and making it easier to engage with the behavioral and spiritual dimensions of recovery.
Q: Will I be conscious during treatment?
A: Yes. During the infusion, you remain awake but enter a dissociative state—a dream-like condition in which your sense of time, space, and self may shift. Dissociation is part of the therapeutic process, creating psychological distance from entrenched patterns and opening space for new perspectives. Your therapist remains with you throughout, and our medical team monitors your vital signs continuously.
Q: What conditions might prevent me from receiving treatment?
A: Certain cardiovascular conditions, uncontrolled hypertension, active psychosis, or a history of certain neurological conditions may be contraindications for IV ketamine therapy. During the medical screening, our clinicians review your full history to identify any factors that might affect safety or efficacy.
Q: How long do the effects last?
A: The neuroplastic window—the period of heightened brain receptivity—lasts for approximately 24 to 72 hours after each infusion, which is why integration work during this time is so important. Clinical outcomes vary by individual, but research suggests that the benefits of the KARE protocol, when combined with ongoing therapy and support, may persist for months.
Taking the next step in recovery
The next step is a medical consultation with Nushama’s care team to determine whether the KARE protocol is right for you. Recovery is possible when treatment addresses the neurobiology of addiction rather than relying solely on willpower. The brain’s reward circuits don’t reset through determination alone—they require medical intervention that corrects the glutamate dysregulation at the heart of alcohol dependency.
The program costs approximately $9,950 and includes medical intake, three ketamine infusions, and 18 hours of mindfulness-based talk therapy. Financing options and veteran discounts are available to make evidence-based care more accessible. Our care team is here to listen, answer questions, and guide you through the next steps. Healing doesn’t happen in isolation—it unfolds in the context of compassionate, evidence-based care and a commitment to doing things differently.
Schedule a consultation to discuss the KARE protocol with our care team and explore your specific situation and recovery goals.
